Financhill
Sell
5

IVVD Quote, Financials, Valuation and Earnings

Last price:
$0.82
Seasonality move :
-40.93%
Day range:
$0.71 - $0.84
52-week range:
$0.35 - $4.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.11x
Volume:
2.6M
Avg. volume:
29.5M
1-year change:
-78.55%
Market cap:
$92.4M
Revenue:
--
EPS (TTM):
-$1.96

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IVVD
Invivyd
$13.6M -$0.10 1529.58% -85.08% $6.67
AMGN
Amgen
$8.9B $5.08 8.14% 257.4% $315.95
AMRX
Amneal Pharmaceuticals
$708.1M $0.15 9.69% 125.42% $11.50
PEPG
PepGen
-- -$0.72 -- -19.05% $12.20
PFE
Pfizer
$17.3B $0.46 -3.03% 29.69% $31.32
TRDA
Entrada Therapeutics
$12.9M -$0.66 -80.31% -128.97% $25.43
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IVVD
Invivyd
$0.77 $6.67 $92.4M -- $0.00 0% --
AMGN
Amgen
$317.17 $315.95 $170.4B 42.01x $2.38 2.88% 5.12x
AMRX
Amneal Pharmaceuticals
$8.62 $11.50 $2.7B 101.17x $0.00 0% 0.96x
PEPG
PepGen
$2.35 $12.20 $76.8M -- $0.00 0% --
PFE
Pfizer
$26.05 $31.32 $147.6B 18.48x $0.43 6.49% 2.33x
TRDA
Entrada Therapeutics
$10.81 $25.43 $406.4M 5.66x $0.00 0% 1.98x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IVVD
Invivyd
-- -4.320 -- 1.47x
AMGN
Amgen
91.09% 0.434 43.85% 0.84x
AMRX
Amneal Pharmaceuticals
104.6% 0.481 101.3% 0.81x
PEPG
PepGen
-- -2.752 -- --
PFE
Pfizer
41.92% 0.618 43.87% 0.82x
TRDA
Entrada Therapeutics
-- 2.917 -- 10.73x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IVVD
Invivyd
$8.5M -$62.3M -- -- -670.01% -$41.1M
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $4.4B
AMRX
Amneal Pharmaceuticals
$262.9M $54.1M -4.58% -587.3% 6.34% $95M
PEPG
PepGen
-- -$24.3M -- -- -- -$19.7M
PFE
Pfizer
$11.9B $3.2B 5.09% 8.91% 4.1% $5.8B
TRDA
Entrada Therapeutics
-- -$5.9M 18.3% 18.3% -15.69% -$32.2M

Invivyd vs. Competitors

  • Which has Higher Returns IVVD or AMGN?

    Amgen has a net margin of -653.11% compared to Invivyd's net margin of 6.9%. Invivyd's return on equity of -- beat Amgen's return on equity of 66.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    IVVD
    Invivyd
    91.33% -$0.51 $83.2M
    AMGN
    Amgen
    65.75% $1.16 $66B
  • What do Analysts Say About IVVD or AMGN?

    Invivyd has a consensus price target of $6.67, signalling upside risk potential of 763.22%. On the other hand Amgen has an analysts' consensus of $315.95 which suggests that it could fall by -0.39%. Given that Invivyd has higher upside potential than Amgen, analysts believe Invivyd is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVVD
    Invivyd
    1 1 0
    AMGN
    Amgen
    9 14 2
  • Is IVVD or AMGN More Risky?

    Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.288%.

  • Which is a Better Dividend Stock IVVD or AMGN?

    Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 2.88% to investors and pays a quarterly dividend of $2.38 per share. Invivyd pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios IVVD or AMGN?

    Invivyd quarterly revenues are $9.3M, which are smaller than Amgen quarterly revenues of $9.1B. Invivyd's net income of -$60.7M is lower than Amgen's net income of $627M. Notably, Invivyd's price-to-earnings ratio is -- while Amgen's PE ratio is 42.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is -- versus 5.12x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVVD
    Invivyd
    -- -- $9.3M -$60.7M
    AMGN
    Amgen
    5.12x 42.01x $9.1B $627M
  • Which has Higher Returns IVVD or AMRX?

    Amneal Pharmaceuticals has a net margin of -653.11% compared to Invivyd's net margin of -4.26%. Invivyd's return on equity of -- beat Amneal Pharmaceuticals's return on equity of -587.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    IVVD
    Invivyd
    91.33% -$0.51 $83.2M
    AMRX
    Amneal Pharmaceuticals
    35.99% -$0.10 $2.4B
  • What do Analysts Say About IVVD or AMRX?

    Invivyd has a consensus price target of $6.67, signalling upside risk potential of 763.22%. On the other hand Amneal Pharmaceuticals has an analysts' consensus of $11.50 which suggests that it could grow by 33.41%. Given that Invivyd has higher upside potential than Amneal Pharmaceuticals, analysts believe Invivyd is more attractive than Amneal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVVD
    Invivyd
    1 1 0
    AMRX
    Amneal Pharmaceuticals
    1 0 0
  • Is IVVD or AMRX More Risky?

    Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amneal Pharmaceuticals has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.898%.

  • Which is a Better Dividend Stock IVVD or AMRX?

    Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amneal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd pays -- of its earnings as a dividend. Amneal Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IVVD or AMRX?

    Invivyd quarterly revenues are $9.3M, which are smaller than Amneal Pharmaceuticals quarterly revenues of $730.5M. Invivyd's net income of -$60.7M is lower than Amneal Pharmaceuticals's net income of -$31.1M. Notably, Invivyd's price-to-earnings ratio is -- while Amneal Pharmaceuticals's PE ratio is 101.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is -- versus 0.96x for Amneal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVVD
    Invivyd
    -- -- $9.3M -$60.7M
    AMRX
    Amneal Pharmaceuticals
    0.96x 101.17x $730.5M -$31.1M
  • Which has Higher Returns IVVD or PEPG?

    PepGen has a net margin of -653.11% compared to Invivyd's net margin of --. Invivyd's return on equity of -- beat PepGen's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IVVD
    Invivyd
    91.33% -$0.51 $83.2M
    PEPG
    PepGen
    -- -$0.68 --
  • What do Analysts Say About IVVD or PEPG?

    Invivyd has a consensus price target of $6.67, signalling upside risk potential of 763.22%. On the other hand PepGen has an analysts' consensus of $12.20 which suggests that it could grow by 419.15%. Given that Invivyd has higher upside potential than PepGen, analysts believe Invivyd is more attractive than PepGen.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVVD
    Invivyd
    1 1 0
    PEPG
    PepGen
    3 0 0
  • Is IVVD or PEPG More Risky?

    Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PepGen has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock IVVD or PEPG?

    Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PepGen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd pays -- of its earnings as a dividend. PepGen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IVVD or PEPG?

    Invivyd quarterly revenues are $9.3M, which are larger than PepGen quarterly revenues of --. Invivyd's net income of -$60.7M is lower than PepGen's net income of -$22.2M. Notably, Invivyd's price-to-earnings ratio is -- while PepGen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is -- versus -- for PepGen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVVD
    Invivyd
    -- -- $9.3M -$60.7M
    PEPG
    PepGen
    -- -- -- -$22.2M
  • Which has Higher Returns IVVD or PFE?

    Pfizer has a net margin of -653.11% compared to Invivyd's net margin of 2.31%. Invivyd's return on equity of -- beat Pfizer's return on equity of 8.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    IVVD
    Invivyd
    91.33% -$0.51 $83.2M
    PFE
    Pfizer
    66.74% $0.07 $152.1B
  • What do Analysts Say About IVVD or PFE?

    Invivyd has a consensus price target of $6.67, signalling upside risk potential of 763.22%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 20.22%. Given that Invivyd has higher upside potential than Pfizer, analysts believe Invivyd is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVVD
    Invivyd
    1 1 0
    PFE
    Pfizer
    6 13 1
  • Is IVVD or PFE More Risky?

    Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

  • Which is a Better Dividend Stock IVVD or PFE?

    Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.49% to investors and pays a quarterly dividend of $0.43 per share. Invivyd pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

  • Which has Better Financial Ratios IVVD or PFE?

    Invivyd quarterly revenues are $9.3M, which are smaller than Pfizer quarterly revenues of $17.8B. Invivyd's net income of -$60.7M is lower than Pfizer's net income of $410M. Notably, Invivyd's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is -- versus 2.33x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVVD
    Invivyd
    -- -- $9.3M -$60.7M
    PFE
    Pfizer
    2.33x 18.48x $17.8B $410M
  • Which has Higher Returns IVVD or TRDA?

    Entrada Therapeutics has a net margin of -653.11% compared to Invivyd's net margin of 3.02%. Invivyd's return on equity of -- beat Entrada Therapeutics's return on equity of 18.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    IVVD
    Invivyd
    91.33% -$0.51 $83.2M
    TRDA
    Entrada Therapeutics
    -- $0.03 $428.7M
  • What do Analysts Say About IVVD or TRDA?

    Invivyd has a consensus price target of $6.67, signalling upside risk potential of 763.22%. On the other hand Entrada Therapeutics has an analysts' consensus of $25.43 which suggests that it could grow by 135.22%. Given that Invivyd has higher upside potential than Entrada Therapeutics, analysts believe Invivyd is more attractive than Entrada Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVVD
    Invivyd
    1 1 0
    TRDA
    Entrada Therapeutics
    4 0 0
  • Is IVVD or TRDA More Risky?

    Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Entrada Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock IVVD or TRDA?

    Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Entrada Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd pays -- of its earnings as a dividend. Entrada Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IVVD or TRDA?

    Invivyd quarterly revenues are $9.3M, which are smaller than Entrada Therapeutics quarterly revenues of $37.4M. Invivyd's net income of -$60.7M is lower than Entrada Therapeutics's net income of $1.1M. Notably, Invivyd's price-to-earnings ratio is -- while Entrada Therapeutics's PE ratio is 5.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is -- versus 1.98x for Entrada Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVVD
    Invivyd
    -- -- $9.3M -$60.7M
    TRDA
    Entrada Therapeutics
    1.98x 5.66x $37.4M $1.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock